AXGN
Price
$55.75Alerts
Change
-$0.60 (-1.06%)
Updated
Nov 20 closing price
Capitalization
2.93B
93 days until earnings call
Intraday BUY SELL Signals
XRAY
Price
$8.29Alerts
Change
-$0.20 (-2.36%)
Updated
Nov 20 closing price
Capitalization
1.89B
102 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AXGN vs XRAY

AXGN vs XRAY Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
AXGN vs. XRAY commentary
Nov 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXGN is a Hold and XRAY is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for AXGN with price predictions
Nov 20, 2026

AXGN's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for AXGN turned positive on October 20, 2026. Looking at past instances where AXGN's MACD turned positive, the stock continued to rise in 43 of 47 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on AXGN as a result. In 66 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.

AXGN moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for AXGN crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.

Following a +15.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXGN advanced for three days, in 266 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

The Aroon Indicator entered an Uptrend today. In 224 of 264 cases where AXGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.

Bearish Trend Analysis

The 10-day RSI Indicator for AXGN moved out of overbought territory on November 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 34 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

AXGN broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.452) is normal, around the industry mean (4.142). P/E Ratio (-74.657) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.080) settles around the average of (0.011) among similar stocks. P/S Ratio (8.961) is also within normal values, averaging (40.124).

The Tickeron Profit vs. Risk Rating rating for this company is 10 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. AXGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for XRAY with price predictions
Nov 20, 2026

XRAY sees MACD Histogram just turned negative

XRAY saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 13, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 53 instances where the indicator turned negative. In 45 of the 53 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for XRAY moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 20 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.

The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XRAY as a result. In 68 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.

XRAY moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for XRAY crossed bearishly below the 50-day moving average on November 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XRAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.

The Aroon Indicator for XRAY entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where XRAY advanced for three days, in 174 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.

XRAY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.396) is normal, around the industry mean (4.964). P/E Ratio (-3.465) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.601) is also within normal values, averaging (4.143). XRAY's Dividend Yield (0.068) is considerably higher than the industry average of (0.006). P/S Ratio (0.557) is also within normal values, averaging (56.876).

The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. XRAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XRAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
AXGN vs XRAY: Fundamental Ratings
AXGN
XRAY
OUTLOOK RATING
1..100
5068
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
6
Undervalued
PROFIT vs RISK RATING
1..100
10100
SMR RATING
1..100
9597
PRICE GROWTH RATING
1..100
3462
P/E GROWTH RATING
1..100
7917
SEASONALITY SCORE
1..100
5019

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AXGN's Valuation (4) in the Medical Specialties industry is in the same range as XRAY (6). This means that AXGN’s stock grew similarly to XRAY’s over the last 12 months.

AXGN's Profit vs Risk Rating (10) in the Medical Specialties industry is significantly better than the same rating for XRAY (100). This means that AXGN’s stock grew significantly faster than XRAY’s over the last 12 months.

AXGN's SMR Rating (95) in the Medical Specialties industry is in the same range as XRAY (97). This means that AXGN’s stock grew similarly to XRAY’s over the last 12 months.

AXGN's Price Growth Rating (34) in the Medical Specialties industry is in the same range as XRAY (62). This means that AXGN’s stock grew similarly to XRAY’s over the last 12 months.

XRAY's P/E Growth Rating (17) in the Medical Specialties industry is somewhat better than the same rating for AXGN (79). This means that XRAY’s stock grew somewhat faster than AXGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AXGNXRAY
RSI
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
79%
Bullish Trend 3 days ago
65%
Momentum
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
75%
MACD
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
74%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
75%
Advances
ODDS (%)
Bullish Trend 12 days ago
83%
Bullish Trend 12 days ago
60%
Declines
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
72%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
75%
Bullish Trend 3 days ago
63%
Aroon
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
75%
COMPARISON
Comparison
Nov 22, 2026
Stock price -- (AXGN: $55.75 vs. XRAY: $8.29)
Brand notoriety: AXGN and XRAY are both not notable
AXGN represents the Medical/Nursing Services, while XRAY is part of the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: AXGN: 51% vs. XRAY: 92%
Market capitalization -- AXGN: $2.93B vs. XRAY: $1.89B
AXGN [@Medical/Nursing Services] is valued at $2.93B. XRAY’s [@Pharmaceuticals: Other] market capitalization is $1.89B. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $837 to $190.22B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $159.96B. The average market capitalization across the [@Medical/Nursing Services] industry is $6.17B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $9.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AXGN’s FA Score shows that 2 FA rating(s) are green while XRAY’s FA Score has 2 green FA rating(s).

  • AXGN’s FA Score: 2 green, 3 red.
  • XRAY’s FA Score: 2 green, 3 red.
According to our system of comparison, AXGN is a better buy in the long-term than XRAY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AXGN’s TA Score shows that 6 TA indicator(s) are bullish while XRAY’s TA Score has 3 bullish TA indicator(s).

  • AXGN’s TA Score: 6 bullish, 4 bearish.
  • XRAY’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, AXGN is a better buy in the short-term than XRAY.

Price Growth

AXGN (@Medical/Nursing Services) experienced а -0.32% price change this week, while XRAY (@Pharmaceuticals: Other) price change was -9.50% for the same time period.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -11.44%. For the same industry, the average monthly price growth was -15.18%, and the average quarterly price growth was -18.29%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -7.82%. For the same industry, the average monthly price growth was -5.08%, and the average quarterly price growth was +4.34%.

Reported Earning Dates

AXGN is expected to report earnings on Feb 23, 2027.

XRAY is expected to report earnings on Mar 04, 2027.

Industries' Descriptions

@Medical/Nursing Services (-11.44% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

@Pharmaceuticals: Other (-7.82% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

View a ticker or compare two or three
Interact to see
Advertisement

XRAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, XRAY has been loosely correlated with NVST. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if XRAY jumps, then NVST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XRAY
1D Price
Change %
XRAY100%
-2.36%
NVST - XRAY
63%
Loosely correlated
-1.55%
ALGN - XRAY
61%
Loosely correlated
-2.82%
QDEL - XRAY
50%
Loosely correlated
-6.73%
KIDS - XRAY
48%
Loosely correlated
-2.37%
COO - XRAY
47%
Loosely correlated
-2.40%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GXPS29.230.22
+0.76%
Global X PureCap MSCI Consumer Staples ETF (GXPS)
IBX15.830.04
+0.25%
Tradr 2X Long IBM Daily ETF (IBX)
XSHQ43.20-1.25
-2.81%
Invesco S&P SmallCap Quality ETF (XSHQ)
NBXG12.62-0.83
-6.17%
Neuberger Next Generation Connectivity Fund Inc.
TSEG1.51-0.35
-18.82%
Leverage Shares 2X Long TSEM Daily ETF (TSEG)